Cargando…
Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus
Background: The effect of clopidogrel, whose mechanism of action differs from that of aspirin, on CRC risk remains unknown. We investigated the effects of clopidogrel and aspirin, either as monotherapy or combined, on colorectal cancer (CRC) risk in patients with Type 2 diabetes mellitus (T2DM). Met...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827090/ https://www.ncbi.nlm.nih.gov/pubmed/31569587 http://dx.doi.org/10.3390/cancers11101468 |
_version_ | 1783465244571467776 |
---|---|
author | Kuan, Yi-Chun Huang, Kuang-Wei Lin, Cheng-Li Luo, Jiing-Chyuan Kao, Chia-Hung |
author_facet | Kuan, Yi-Chun Huang, Kuang-Wei Lin, Cheng-Li Luo, Jiing-Chyuan Kao, Chia-Hung |
author_sort | Kuan, Yi-Chun |
collection | PubMed |
description | Background: The effect of clopidogrel, whose mechanism of action differs from that of aspirin, on CRC risk remains unknown. We investigated the effects of clopidogrel and aspirin, either as monotherapy or combined, on colorectal cancer (CRC) risk in patients with Type 2 diabetes mellitus (T2DM). Methods: We conducted a cohort study using Taiwan National Health Insurance Research Database. Four groups comprising 218,903 patients using aspirin monotherapy, 20,158 patients using clopidogrel monotherapy, 42,779 patients using dual antiplatelet therapy, and 281,840 nonuser matched controls were created using propensity score matching. Cox proportional hazards regression was used to evaluate the CRC risk during follow-up. Results: During the 13-year follow-up period, we found 9431 cases of CRC over 3,409,522 person-years. The overall incidence rates of CRC were 2.04, 3.45, 1.55, and 3.52 per 1000 person-years in the aspirin, clopidogrel, dual antiplatelet, and nonuser cohorts, respectively. The adjusted hazard ratios (aHRs) were 0.59 (95% confidence interval [CI], 0.56–0.61), 0.77 (95% CI, 0.68–0.87), and 0.37 (95% CI, 0.33–0.40) for the aspirin, clopidogrel, and dual antiplatelet cohorts, respectively. Dose- and duration-dependent chemopreventive effects were observed in the three cohorts. |
format | Online Article Text |
id | pubmed-6827090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68270902019-11-18 Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus Kuan, Yi-Chun Huang, Kuang-Wei Lin, Cheng-Li Luo, Jiing-Chyuan Kao, Chia-Hung Cancers (Basel) Article Background: The effect of clopidogrel, whose mechanism of action differs from that of aspirin, on CRC risk remains unknown. We investigated the effects of clopidogrel and aspirin, either as monotherapy or combined, on colorectal cancer (CRC) risk in patients with Type 2 diabetes mellitus (T2DM). Methods: We conducted a cohort study using Taiwan National Health Insurance Research Database. Four groups comprising 218,903 patients using aspirin monotherapy, 20,158 patients using clopidogrel monotherapy, 42,779 patients using dual antiplatelet therapy, and 281,840 nonuser matched controls were created using propensity score matching. Cox proportional hazards regression was used to evaluate the CRC risk during follow-up. Results: During the 13-year follow-up period, we found 9431 cases of CRC over 3,409,522 person-years. The overall incidence rates of CRC were 2.04, 3.45, 1.55, and 3.52 per 1000 person-years in the aspirin, clopidogrel, dual antiplatelet, and nonuser cohorts, respectively. The adjusted hazard ratios (aHRs) were 0.59 (95% confidence interval [CI], 0.56–0.61), 0.77 (95% CI, 0.68–0.87), and 0.37 (95% CI, 0.33–0.40) for the aspirin, clopidogrel, and dual antiplatelet cohorts, respectively. Dose- and duration-dependent chemopreventive effects were observed in the three cohorts. MDPI 2019-09-29 /pmc/articles/PMC6827090/ /pubmed/31569587 http://dx.doi.org/10.3390/cancers11101468 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kuan, Yi-Chun Huang, Kuang-Wei Lin, Cheng-Li Luo, Jiing-Chyuan Kao, Chia-Hung Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title | Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title_full | Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title_fullStr | Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title_full_unstemmed | Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title_short | Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus |
title_sort | effects of aspirin or clopidogrel on colorectal cancer chemoprevention in patients with type 2 diabetes mellitus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827090/ https://www.ncbi.nlm.nih.gov/pubmed/31569587 http://dx.doi.org/10.3390/cancers11101468 |
work_keys_str_mv | AT kuanyichun effectsofaspirinorclopidogreloncolorectalcancerchemopreventioninpatientswithtype2diabetesmellitus AT huangkuangwei effectsofaspirinorclopidogreloncolorectalcancerchemopreventioninpatientswithtype2diabetesmellitus AT linchengli effectsofaspirinorclopidogreloncolorectalcancerchemopreventioninpatientswithtype2diabetesmellitus AT luojiingchyuan effectsofaspirinorclopidogreloncolorectalcancerchemopreventioninpatientswithtype2diabetesmellitus AT kaochiahung effectsofaspirinorclopidogreloncolorectalcancerchemopreventioninpatientswithtype2diabetesmellitus |